Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance

J Cardiovasc Magn Reson. 2010 Oct 7;12(1):56. doi: 10.1186/1532-429X-12-56.

Abstract

Background: The new gold standard for myocardial viability assessment is late gadolinium enhancement-cardiovascular magnetic resonance (LGE-CMR); this technique has demonstrated that the transmural extent of scar predicts segmental functional recovery. We now asked how the number of viable and number of viable+normal, segments predicted recovery of global left ventricular (LV) function in patients undergoing CABG. Finally, we examined which segmental transmural threshold of scarring best predicted global LV recovery.

Methods and results: Fifty patients with reduced LV ejection fraction (EF) referred for CABG were recruited, and 33 included in this analysis. Patients underwent CMR to assess LV function and viability pre-operatively at 6 days and 6 months. Mean LVEF 38% ± 11, which improved to 43% ± 12 after surgery. 21/33 patients improved EF by ≥3% (EF before 38% ± 13, after 47% ± 13), 12/33 did not (EF before 39% ± 6, after 37% ± 8). The only independent predictor for global functional recovery after revascularisation was the number of viable+normal segments: Based on a segmental transmural viability cutoff of <50%, ROC analysis demonstrated ≥10 viable+normal segments predicted ≥3% improvement in LVEF with a sensitivity of 95% and specificity of 75% (AUC = 0.9, p < 0.001). Transmural viability cutoffs of <25 and <75% and a cutoff of ≥4 viable segments were less useful predictors of global LV recovery.

Conclusions: Based on a 50% transmural viability cutoff, patients with ≥10 viable+normal segments improve global LV function post revascularisation, while patients with fewer such segments do not. LGE-CMR is a simple and powerful tool for identifying which patients with impaired LV function will benefit from CABG.

Trial registration: Research Ethics Committee Unique Identifier: NRES:05/Q1603/42. The study is listed on the Current Controlled Trials Registry: ISRCTN41388968.URL: http://www.controlled-trials.com.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Contrast Media
  • Coronary Artery Bypass*
  • England
  • Gadolinium DTPA
  • Heart Failure / diagnosis*
  • Heart Failure / physiopathology
  • Heart Failure / surgery
  • Humans
  • Magnetic Resonance Imaging*
  • Middle Aged
  • Myocardium / pathology*
  • Patient Selection
  • Predictive Value of Tests
  • Randomized Controlled Trials as Topic
  • Recovery of Function
  • Stroke Volume
  • Time Factors
  • Treatment Outcome
  • Ventricular Function, Left*

Substances

  • Contrast Media
  • gadodiamide
  • Gadolinium DTPA

Associated data

  • ISRCTN/ISRCTN41388968